MIC: 0.015-0.12 µg/mL ( E. coli )

Sulopenem has the potential for uncomplicated and complicated urinary tract infections and intra-abdominal infections treatment, including multidrug-resistant (MDR) infections and infections attributable to quinolone-nonsusceptible and/or extended-spectrum β-lactamase (ESBL)-producing Gram-negative bacilli.
Sulopenem inhibits the growth of most isolates of aerobic and anaerobic Gram-positive and Gram-negative bacteria, including methicillin-susceptible Staphylococcus aureus , Streptococcus pneumoniae (penicillin-susceptible and -resistant isolates), group A and B β-hemolytic streptococci, Listeria monocytogenes , Enterobacteriaceae , Haemophilus influenzae , and Moraxella catarrhalis but excluding P. aeruginosa and Stenotrophomonas maltophilia , at a concentration of ≤1 μg/mL.

The protective effects of Sulopenem in murine experimental systemic infections are superior to those of Imipenem/Cilastatin. In murine experimental mixed infection with Escherichia coli and Bacteroides fragilis , Sulopenem has lower ED ₅₀ . In guinea pigs experimental lung infection with Klebsiella pneumoniae , Sulopenem is more effective than CZON or Cefotiam.